Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal
by Zacks Equity Research
While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals
by Zacks Equity Research
Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.
Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More
by Zacks Equity Research
Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.
Gilead (GILD) Down 7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment
by Zacks Equity Research
VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.
Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22
by Zacks Equity Research
Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 2022.
Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More
by Zacks Equity Research
Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.
Gilead (GILD) Veklury Retains Activity Against Omicron Variant
by Zacks Equity Research
Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.
How Are Biotech ETFs Reacting to These Q4 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.
Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges
by Zacks Equity Research
Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.
Gilead Sciences (GILD) Q4 Earnings Miss Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -54.90% and 9.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Big Data for Q4, Econ to Start a New Month
by Mark Vickery
We've got a big day ahead with both economic prints and Q4 earnings reports.
Wall Street Waits for Major Economic Data This Week
by Zacks Equity Research
Wall Street Waits for Major Economic Data This Week.
Should Value Investors Pick Gilead Sciences (GILD) Stock?
by Zacks Equity Research
Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.
Should You Buy Gilead Sciences (GILD) Ahead of Earnings?
by Zacks Equity Research
Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid
by Zacks Equity Research
Pfizer's (PFE) oral COVID-19 drug, Paxlovid, gets recommendation from the CHMP for its authorization in Europe for treating mild-to-moderate COVID-19 in patients at increased risk of hospitalizations.
Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.
5 Corporate Giants Likely to Gain From Q4 Earnings Next Week
by Nalak Das
Five corporate behemoths will report fourth-quarter 2021 earnings results next week. These are: TMO, FB, GOOGL, GILD and UPS.
Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.
Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA
by Zacks Equity Research
Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.
The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead
by Zacks Equity Research
Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.